Incidence and prevalence of drugs used for chronic diseases in survivors of adult‐onset gynaecological cancer – A nationwide cohort study

Abstract

Objectives To evaluate both incidence and prevalence of drugs used for chronic diseases in survivors of adult‐onset gynaecological cancer. Design A prospective study. Setting Population‐based registries. Population 1.76 million women, including 17 500 women with gynaecological cancers. Methods Data from the Cancer Registry of Norway was linked to the Norwegian Prescription Database and other national databases. Main Outcome Measures Prevalence ratios (PRs) and hazard ratios (HRs), with 95% confidence intervals (CIs), of dispensed drugs in gynaecological cancer patients (up to 15 years after diagnosis) were estimated by log‐binomial and Cox regression, respectively, with cancer‐free women as reference. Results For gynaecological cancer patients, the incidence of drugs used for pain control was higher than in cancer‐free women, especially the first 5 years after diagnosis, and the prevalence was high at least 10 years after. The prevalence of sex hormones was high in women with gynaecological cancer at least 10 years after diagnosis (cervical and ovarian cancer PR = 23, 95% CI 18–30 and PR = 29, 95% CI 15–38, respectively), but low in cancer‐free women (0.3%). Patients with uterine corpus cancer had a higher prevalence of antidiabetics before and at least 10 years after diagnosis, most pronounced in women diagnosed before age 50 (PR = 10, 95% CI 5.0–21). The prevalence of antidepressants was moderately elevated in women with gynaecological cancers. Conclusions Gynaecological cancer survivors, particularly cervical and ovarian cancer survivors, had an increased long‐term use of drugs for pain control and sex hormones. Survivors of uterine corpus cancer used antidiabetics more often, both before and after diagnosis.

Gynecological disorders as factors that could cause cervical neoplasia

“…The identification of numerous infections in the same lady accounts for the variance of 670. Bjørge et al (2023) linked data from the Cancer Registry of Norway to the Norwegian Prescription Database and other national databases in which 1.76 million women were participants, including 17 500 women with gynecological cancers.…”